Efficacy and safety of ruxolitinib in ineffective erythropoiesis suppression as a pretransplantation treatment for pediatric patients with beta-thalassemia major.
Galina OvsyannikovaDmitry BalashovIrina DeminaLarisa ShelikhovaAlexey PshonkinMichael MaschanGalina NovichkovaAlexey A MaschanNataliya S SmetaninaPublished in: Pediatric blood & cancer (2021)
Ruxolitinib is promising as a short-term pre-HSCT treatment for pediatric patients with TDT and pronounced IE.